EMG
MACK

Ellington Management Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Ellington Management Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,279
Closed -$558K – 911
2014
Q4 		$558K Buy
+6,279
New +$457K 0.19% 163
2013
Q3 		– Sell
-5,821
Closed -$309K – 1079
2013
Q2 		$309K Buy
+5,821
New +$255K 0.06% 498

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Ellington Management Group's MACK Position: Q1 2015 in Review

Ellington Management Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2015, closing a stake of 6,279 shares — an estimated $558K sold.

Ellington Management Group first reported a position in MACK in Q2 2013 and held it in 2 quarters. The position peaked at $558K in Q4 2014. 152 funds tracked by Wall St. Rank hold MACK as of Q1 2015.

  • Ellington Management Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Ellington Management Group sold 6,279 Merrimack Pharmaceuticals, Inc. shares in Q1 2015, an estimated $558K.
  • Ellington Management Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Ellington Management Group's Merrimack Pharmaceuticals, Inc. position peaked at $558K in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2015.

Based on Ellington Management Group's 13F filing for Q1 2015, filed 15 May 2015.